This area of the web site contains all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules and was last updated on 21 November 2022.

GENinCode is a U.K. limited company specializing in risk assessment and prediction of cardiovascular disease. Cardiovascular disease (CVD) is a broad disease classification which includes coronary artery disease such as angina and myocardial infarction often referred to as heart attack. CVD also includes stroke, heart failure, hypertension, venous thromboembolism and other vascular heart diseases and is the leading cause of death and disability worldwide accounting for 1 in every 4 deaths in the United States.

GENinCode products provide genetic information to enable patients and healthcare practitioners to assess and predict the onset of cardiovascular disease. Our tests and reports help inform health care practitioners and patients of their health risk enabling behavioral and lifestyle changes alongside delivering the most effective treatment pathways.

GENinCode U.K. Limited was incorporated in September 2018 and subsequently acquired the products, assets and know-how of the Ferrer inCode and the Gendiag.exe businesses, then part of Ferrer, a large pharmaceutical and healthcare company based in Spain. GENinCode has a strong, granted intellectual property portfolio with a vision to educate patients on cardiovascular risk assessment using the predictive capability of GENinCode products and lifestyle choices to help improve patient outcomes.

GENinCode has amassed significant investment over the past 15 years in its research and development of predictive and preventative technology to cardiovascular disease.

GENinCode has developed a proprietary online cloud-based system Sitab® to integrate patients clinical and genetic data and provide online reporting capabilities to health care practitioners.

The Core Products of GENinCode Include:

  • Cardio inCode® - Score and Check® - Coronary predictive/risk assessment.
  • Thrombo inCode® - Hematology, Recurrent Pregnancy Loss and Oncology, Thrombosis (blood clots) predictive/risk assessment.
  • Lipid inCode® - Familial Hypercholesterolemia Diagnosis and risk stratification.
  • SudD inCode® - Hereditary Cardiomiopathies diagnosis, Risk assessment for sudden cardiac events.

Latest Share Price


Latest News

Financial Calendar

Interim Results 27 September 2022


Who Are We


Investor Alerts

GENinCode UK Limited
Oxford Science Park
John Eccles House
Robert Robinson Avenue
Oxford - UK
(+44) 186 5955 847
GENinCode S.L.U.
Rambla Egara, 235, ES- 08224
(+34) 936 690 321